High Flow Nasal Therapy in Covid 19 Patient

Study Overview
=================
Brief Summary
-----------------
This study aims to To identify factors that predict success of high flow nasal therapy in covid19 patients .

Detailed Description
-----------------
Coronavirus disease 2019 (COVID-19) is a potentially fatal infection caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)[1]. The highly contagious nature and exponential spread of SARS-CoV-2, coupled with its potential for a rapid progressto acute respiratory distress syndrome (ARDS), has overwhelmed health care systems globally, contributing to the high mortality rates in early reports [1,2]. The initial approach for respiratory support for severe COVID-19 pneumonia centredaround invasive mechanical ventilation and the standard lung protective strategy recommended for ARDS[3]. This may have been detrimental to a proportion of patients due to ventilator induced lung injury (VILI) and associated systemic inflammation[4]. Furthermore, other strategies to improve oxygenation may be more appropriate in patients with hypoxemic respiratory failure who do not require ventilatorysupport[4]. High-flow nasal oxygen (HFNO) is delivered by an air/oxygen blender, an active humidifier, a single heated circuit, and a nasal interface. It delivers adequately heated and humidified medical gas at flow-rates of up to 60L/min, and is considered to have a number of physiological benefits, including the reduction of anatomical dead space and work of breathing, the provision of a constant fraction of inspired oxygen with adequate humidification and a degree of positive end-expiratory pressure (PEEP) [5,6].

Official Title
-----------------
Predictors of Success of High Flow Nasal Therapy in Covid 19 Patients

Conditions
-----------------
High Flow Nasal Therapy

Intervention / Treatment
-----------------
* Other: high flow nasal therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All Patients above 18 y old that will be diagnosed as COVID 19 based on PCR testing, who fulfil criteria that indicate need for high flow nasal therapy. Exclusion Criteria: o Children less than 18 y old Oropharyngeal and Nasopharyngeal swap negative patients Patients who will refuse inclusion in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group A<br>Covidpatient Who pass on high flow nasal therapy | Other: high flow nasal therapy<br>* effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive<br>|
| group B<br>Covidpatient who failed on high flow nasal therapy and need NIV | Other: high flow nasal therapy<br>* effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| predictors of success of high flow nasal therapy in covid 19 patients | This study aims to To identify factors that predict success of high flow nasal therapy in covid19 patients | Baseline |